Global Xerostomia Therapeutics Market Trends, Forecast Report 2025-2037
Xerostomia Therapeutics Market size was over USD 1.3 billion in 2024 and is likely to exceed USD 2.5 billion by the end of 2037, growing at over 6.2% during the forecast period i.e., between 2025-2037. In 2025, the industry size of xerostomia therapeutics is assessed at USD 1.5 billion.
The xerostomia therapeutics market is witnessing expansion owing to the growing burden of drug-induced dry mouth, Sjögren’s syndrome, and an increase in the aging demographics. The National Institute of Health report in 2024 estimates that above 22% of adults who are over 65 suffer from chronic symptoms. Besides, the Sjögren’s Foundation in 2023 stated that autoimmune conditions such as Sjögren’s syndrome affect 4.3 million individuals in the U.S., meanwhile, 42% to 55% of cancer patients who received radiotherapy are more likely to develop severe dry mouth. Therefore, these rising instances enhance the demand for xerostomia therapeutics for which APIs are primarily being sourced from China and India, i.e., 40% and 30%.
Further, the growth in this sector is stimulated by the presence of the supply chain aspect, which is fueled by the U.S. and EU-based firms that supply 80% of OTC saliva substitutes. Meanwhile, the producer price index of xerostomia drugs has increased by 3.5% due to the regulatory compliance. Simultaneously, the consumer price index witnessed an annual rise of 5.4% owing to the heightened demand, thus ensuring global elasticity. According to the USITC data in 2024, the U.S. is the major importer of xerostomia APIs, which grew by 13.7% year over year in 2023, further denoting a strong necessity.
